LifeSci Capital analyst Charles Zhu has maintained their bullish stance on MRUS stock, giving a Buy rating on February 13.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Charles Zhu has given his Buy rating due to a combination of factors. Merus has received a Breakthrough Therapy Designation (BTD) from the FDA for its combination treatment of petosemtamab and pembrolizumab, which is significant for first-line treatment in PD-L1+ head and neck cancer. This designation underscores the therapy’s potential as a leading option among emerging treatments, demonstrated by a 67% overall response rate in a recent clinical study.
Additionally, the BTD applies broadly to the entire PD-L1+ population, suggesting a wide applicability of the treatment. Merus’s strategic designation achievements suggest a promising clinical future, further supported by the company’s financial position, which includes an estimated four years of operational cash. The differentiation of Merus’s therapy from competitors, who lack similar designations, supports the positive outlook for its stock.
In another report released on February 13, Piper Sandler also initiated coverage with a Buy rating on the stock with a $84.00 price target.